WO2019004590A1 - Composition for treating skin cell damage caused by fine dust, for strengthening skin barrier, and for anti-aging or anti-inflammation, containing mentha arvensis extract - Google Patents

Abstract

The present specification relates to an external-use skin preparation composition containing a Mentha Arvensis extract as an active ingredient, and provides a composition for treating skin damage caused by fine dust, the composition regulating, to a normal level, the expression of any one or more selected from the group consisting of IL-1a(NM_000575), IL-1B(NM_000576), IL-36G(NM_019618), S100A7(NM_002963), LCE3D(NM_032563), PTGS2(NM_000963) and XDH(NM_000379), which are genes in skin cells and of which the expression is affected by fine dust. By using the composition for treating skin damage caused by fine dust, gene expression changed by fine dust can return to the normal level such that skin cell damage can be treated.

Description

For the care of skin cell damage caused by fine dust containing mint extract, for strengthening skin barrier, and for anti-aging or anti-inflammatory composition

Disclosed herein are compositions for treating skin cell damage caused by fine dusts. More specifically, as compared to the steady-state skin cells, thereby significantly change and the like of the skin cells biomarker gene expression level is changed by the fine dust to care the skin cell damage, peppermint second (Mentha Arvensis < / RTI > extract.

Skin is a part of the body that is directly exposed to the external environment. It acts as a protective layer to protect important organs of our body, as well as controlling water evaporation and protecting the body from external infections. However, even skin that prevents virus penetration from the outside, if exposed to excessive ultraviolet rays or pollutants, causes skin irritation, and especially, it is injured by yellow dust accompanied by strong wind and dirt.

Dust is a phenomenon in which small sand or loess is floated in the inland deserts of China and Mongolia, and is transported far away in the upper winds, falling near the ground. In Korea, yellow dust occurs periodically every spring. Dusts are a complex of organic matter and inorganic matter, and their physical characteristics and constituents are very diverse depending on when and where they occur, and they also contain metal components that can biologically affect them. Large dust-like particles, such as dusts, usually stay in the source or periphery, dust particles of small particle size are introduced into the domestic area, and when such dust is inhaled, the dust collects in the gas- Of the patients. In addition, skin cell damage has been observed to increase in skin of people residing in dusty, dusty areas.

 On the other hand, among the constituent layers of the skin, the epidermis plays an important role in preventing water evaporation inside the human body. The epidermis is divided into stratum corneum, granular layer, superficial layer, and basal layer in order from the outside. Cells of stratum corneum act like bricks, and interstitial lipids between keratinocytes act like mortar to form skin barrier. In addition, a healthy human keratinocyte has a high concentration of natural moisturizing factor (NMF) to help maintain moisture in the skin. For example, substances such as amino acids are water-soluble, Thereby suppressing drying.

However, as it is nowadays, there is a tendency to adjust the temperature of the air / heating due to the change of environment or life pattern, the stress caused by various stresses and environmental pollution in the social life, frequent washing according to make- Due to various causes such as aging of the skin, the skin becomes dry, the surface becomes rough, the skin becomes loose, the moisture is lost, and the appearance of the skin does not appear, and thus the need for a skin moisturizer increases . Excessive physical and chemical stimuli, ultraviolet rays, stress and nutrient deficiency, which are externally received, can lower the normal functions of the skin and promote elasticity loss, keratinization and wrinkle formation. Especially, . Excessive physical, chemical stimuli, ultraviolet rays, and stress from the outside of the skin lower the normal functions of the skin and promote skin aging phenomenon such as loss of elasticity, keratinization, and wrinkle formation. Especially, .

It is known that IL-36G is a useful biomarker in psoriasis caused by skin barrier weakness (see Non-Patent Document 1). It is also known that S100A7 is an index related to atopic dermatitis and psoriasis due to impairment of skin barrier function (see Non-Patent Document 2). It is also known that LCE3D is an index related to the psoriasis risk gene (see Non-Patent Document 3).

In addition, interleukin-1 is classified as a senescence-associated secretory phenotype (SASP), and interleukins 1a and 1b (IL-1a and IL-1b) are representative aging markers and exhibit cell senescence (See Non-Patent Document 4). It is also known that IL-1α, IL-1b and PTGS2 are involved in skin inflammation, and XDH is indicative of oxidative stress induced by prolonged exposure to stimulus sources and, consequently, is indicative of exogenous skin aging Patent Document 5). It is also known that the expression level of PTGS2 (= COX-2) and IL-1a is increased in skin cells exposed to stimulus source in relation to skin inflammation (see Non-Patent Document 6). XDH (xanthine dehydrogenase) It is also known to be involved in skin aging, an indicator of oxidative stress.

Prior art literature

(IL-1F9) Is a Biomarker for Psoriasis Skin Lesions ", Journal of Investigative Dermatology, Volume 135, 2015. (Non-Patent Document 1) AM D'Erme et al.

(Non-Patent Document 2) Son et al, " S100A7 (psoriasin) inhibits human epidermal differentiation by enhanced IL-6 secretion through IJB / NF-JB signaling ", Experimental Dermatology, John Wiley & Sons A /

(Non-Patent Document 3) Bergboer et al, " Psoriasis Risk Genes of the Late Corned Envelope-3 Group Are Distinctly Expressed Compared with Genes of Other LCE Groups ", The American Journal of Pathology, Vol. 178, No. 4, April 2011.

(Non-Patent Document 4) Jean-Philippe Coppe, et al, "The Senescence-Associated Secretory Phenotype: The Dark Side of Tumor Suppression", Annual Review of Pathology: Mechanisms of Disease, volume 5, 2010.

(Non-Patent Document 5) Kim, HJ, et al., "Transcriptome analysis of airborne PM _2.5 -induced detrimental effects on human keratinocytes", Toxicology Letters 273, 26-35,

(Non-Patent Document 6) Natalia D Magnani, et al., "Skin Damage Mechanisms Related to Airborne Particulate Matter Exposure", toxicological sciences, 149 (1), 2016, 227-236.

Accordingly, the present inventors have found that fine dusts adversely affect the skin, and by such an influence, they also affect the expression of skin cell genes, thereby causing symptoms such as skin cell damage.

Accordingly, in one aspect, the present invention provides a composition for care of damage of skin cells caused by fine dust particles.

In order to achieve the above object, in one aspect, the present invention provides a composition for external application for skin comprising an extract of peppermint powder as an active ingredient, comprising IL-1a (NM_000575), a gene in a skin cell to which an expression amount is affected by fine dust, , Which regulate at least one expression level selected from the group consisting of IL-1B (NM_000576), IL-36G (NM_019618), S100A7 (NM_002963), LCE3D (NM_032563), PTGS2 (NM_000963), XDH A composition for care of skin caused by dust is provided.

In one aspect, by using the composition for care of skin damage due to fine dust provided by the present invention, the amount of gene expression changed by the fine dust can be returned to a normal level and skin cell damage can be cared.

In one aspect, by using the anti-aging composition and the anti-inflammatory composition provided by the present invention, the amount of gene expression, which is changed by inflammation or aging stimulation, can be returned to a normal level and skin cell damage can be reduced.

In one aspect, by using the composition for skin barrier enhancement provided by the present invention, it is possible to reduce the damage of skin cells by returning the amount of gene expression, which is changed by a stimulus source causing skin barrier weakness, to a normal level.

1 shows the cell survival rate by treatment with a fine dust extract, wherein ADSP represents Asian dust-storm particles, and PM10 (Particulate matter 10) represents fine dust particles having a particle size of 10 μm And PM2.5 (Particulate matter 2.5) represents fine dust having a particle size of 2.5 mu m.

FIG. 2A shows that mRNA expression of the S100A7 gene is increased in PM2.5 fine dust-stimulated skin cells.

FIG. 2B shows that mRNA expression of the IL-1A gene is increased in PM2.5 fine dust-stimulated skin cells.

FIG. 2C shows that mRNA expression of IL-1B gene is increased in PM2.5 fine dust-stimulated skin cells.

FIG. 2d shows that mRNA expression of IL-36G gene is increased in skin cells stimulated by PM2.5 fine particles.

FIG. 2E shows that the amount of mRNA expression of the PTGS2 gene is increased in PM2.5 fine dust-stimulated skin cells.

FIG. 2f shows that the amount of mRNA expression of the LCE3D gene is increased in the skin cells stimulated by PM2.5 fine particles.

FIG. 2g shows that the amount of mRNA expression of the XDH gene is increased in the skin cells stimulated by PM2.5 fine particles.

FIG. 3A shows that the expression level of the S100A7 gene changed in the skin cells stimulated by the fine dust was returned to a normal level by treatment with the extract of Mint.

FIG. 3B shows that the expression level of the IL-1A gene changed in the skin cells stimulated by the fine dust was returned to the normal level by treatment with the extract of Mint.

FIG. 3C shows that the expression level of IL-1B gene changed in skin cells stimulated by fine dust returns to a normal level by treatment with mint extract.

FIG. 3D shows that the expression level of IL-36G gene changed in skin cells stimulated by fine dust returns to a normal level by treatment with mint extract.

FIG. 3E shows that the expression level of PTGS2 gene changed in the skin cells stimulated by the fine dust was returned to the normal level by treatment with the extract of Mint.

FIG. 3f shows that the expression level of the LCE3D gene changed in the skin cells stimulated by the fine dust is returned to the normal level by the treatment of the extract of the mint extract.

FIG. 3g shows that the expression amount of the XDH gene changed in the skin cells stimulated by the fine dust was returned to the normal level by the treatment with the extract of mint extract.

Hereinafter, the present invention will be described in detail.

Mentha Arvensis is a perennial herbaceous perennial plant belonging to the monocotyledonous plant of the monocotyledonous plant. The peppermint is characterized by a refreshing and refreshing flavor, and its leaves and stems grow in a cool climate. It mainly contains a menthol ingredient and emits a unique flavor. It also contains nutritional ingredients such as vitamins.

In one aspect of the invention, the composition comprises a mint extract.

In one aspect, leaf or stem of peppermint can be used, but is not limited thereto.

The microbial added peppermint can be specifically fermented at 22-30 ° C for 24-72 hours. In one embodiment, the extract is fermented at 26 DEG C for about 48 hours.

In one aspect of the invention, the mint extract may be extracted with a particular extraction solvent to form a mint extract.

In one aspect of the present invention, the mint extract may be prepared by extracting leaves or stems of mint leaves with water or an organic solvent. Specifically, the leaves or stems of peppermint are selected from the group consisting of water, C ₁ -C ₆ anhydrous or lower alcohol, acetone, butylene glycol, ethyl acetate, diethyl acetate, diethyl ether, benzene, chloroform and hexane May be prepared by extraction with one or more extraction solvents.

In one aspect, the mint extract may be extracted at room temperature.

In one aspect, the mint extract may be obtained by extracting with the extraction solvent, followed by addition of one or more of filtration, concentration, separation or drying. In particular, the mint extract may be subjected to one or more filtration steps, and in one embodiment, it is subjected to two filtration steps.

In one embodiment, the separation process may include a centrifugation process.

Specifically, the extraction can be carried out in the presence of water, a C ₁ -C ₆ anhydrous or a lower alcohol, a polar solvent comprising acetone and butylene glycol, and a polar solvent including ethyl acetate, diethyl acetate, diethyl ether, benzene, chloroform and hexane And a low polarity solvent may be used as a solvent.

More specifically, the solvent may be 50-90% ethanol aqueous solution, and may be 60-80% ethanol or 65-75% ethanol aqueous solution. When the solvent is an aqueous 50 to 90% ethanol solution, the active ingredient can be effectively extracted from the peppermint. In one embodiment, the solvent may be about 70% aqueous ethanol solution.

In one aspect, the extract may be concentrated under reduced pressure to an appropriate temperature in a distillation apparatus equipped with a cooling condenser after extraction.

However, the extract of peppermint powder according to the present invention can be extracted by a conventional method in the art, and is not limited by the above-mentioned method.

In one aspect of the present invention, the composition may comprise from 0.000001 to 30% by weight of peppermint root extract, based on the total weight of the composition. When the content thereof is 0.000001 to 30% by weight, the skin care effect by fine dust caused by the mint extract is excellent.

More specifically, 0.0000001 wt% or more, 0.0000005 wt% or more, 0.0000007 wt% or more, 0.0000009 wt% or more, 0.0000009 wt% or more, 0.000001 wt% or more, 0.000002 wt% or more, 0.000004 wt% or more, 0.000006 wt% or more, 0.000008 wt. At least 0.00003% by weight, at least 0.00005% by weight, at least 0.00007% by weight, at least 0.00009% by weight, at least 0.00009% by weight, at least 0.0001% by weight, at least 0.0003% by weight, at least 0.0005% by weight, at least 0.0007% by weight, % Or more, 0.01 wt% or more, 0.1 wt% or more, 1 wt% or more, 3 wt% or more, 5 wt% or more, 7 wt% or more, 9 wt% or more, 10 wt% or more, 13 wt% or more, Or more, 17 wt% or more, 19 wt% or more, 21 wt% or more, 23 wt% or more, 25 wt% or more, 27 wt% or more, 29 wt% or more, 30 wt% or more, 31 wt% 32 weight% or less, 31 weight% or less, 30 weight% or less, 29 weight% or less, 28 weight% or less, 26 weight% or less, 24 weight % Or less, 22 wt% or less, 20 wt% or less, 18 wt% or less, 16 wt% or less, 14 wt% or less, 12 wt% or less, 10 wt% or less, 9 wt% or less, 8 wt% % Or less, 4 wt% or less, 2 wt% or less, 1 wt% or less, 0.1 wt% or less, 0.09 wt% or less, 0.04 wt% or less, 0.01 wt% or less, 0.006 wt% or less, 0.001 wt% 0.000003 wt.% Or less, 0.00003 wt.% Or less, 0.00001 wt.% Or less, 0.00001 wt.% Or less, 0.000009 wt.% Or less, 0.000007 wt.% Or less, 0.000005 wt. %, 0.0000007 wt% or less, 0.0000005 wt% or less, 0.0000003 wt% or less, 0.0000002 wt% or less, 0.0000001 wt% or less, or 0.00000009 wt% or less.

Another aspect of the present invention includes skin care care applications for fine dusts of the composition.

A method for skin care damage caused by fine dust of the object in another aspect of the invention, the method peppermint second (Mentha Comprising administering an effective amount of an Arvensis extract to a subject in need thereof.

Peppermint seconds in the manufacture of a composition for the skin damage caused by fine dust care in another aspect of the present invention (Mentha Arvensis ) extracts.

Another aspect of the present invention provides Mentha Arvensis extract for skin damage care by fine dust.

As used herein, the term " fine dust " refers to a particulate matter that is a very small material that is invisible to the naked eye and that floats or drifts in the air for a long time. Particularly, particulate matter having a particle size of 2.5 μm or less is called "ultrafine dust". In the present invention, "fine dust" is also intended to include "ultrafine dust".

As used herein, the term " care " refers to effective prevention of skin cells from stimulation and inhibition, prevention, or recovery (restoration) of changes in the expression level of a specific gene by stimulation.

In one aspect, the present invention provides a composition for inhibiting damage of skin cells caused by fine dusts by controlling the expression level of a specific gene in skin cells damaged by fine dust to a normal level.

Specifically, in the present invention, the genes in the skin cells to which the expression amount is affected by the fine dust include IL-1α (NM_000575), IL-1B (NM_000576), IL-36G (NM_019618), S100A7 (NM_002963), LCE3D ), PTGS2 (NM_000963), XDH (NM_000379), and the like. IL-1B (NM_000575), IL-36G (NM_019618), S100A7 (NM_002963), LCE3D (NM_032563), PTGS2 (NM_000963) and XDH (NM_000379) Since it is a gene, the amount of expression of these genes is suppressed and regulated to a normal level, thereby suppressing damage of skin cells.

The genes whose expression levels are increased by fine dusts used in the present invention are shown in [Table 1]. [Table 1] shows the gene whose expression amount is increased by fine dust. In these tables, Name means the genebank accession ID of NCBI, Gene Symbol means the official gene symbol, Gene title means the name of each gene . Such contents can be confirmed through the description in Non-Patent Document 1.

Increase gene
Name	GeneSymbol	Gene title
NM_002963	S100A7	S100 calcium binding protein A7
NM_032563	LCE3D	late cornified envelope 3D
NM_019618	IL36G	interleukin 36, gamma
NM_000576	IL1B	interleukin 1, beta
NM_000575	IL1A	interleukin 1, alpha
NM_000963	PTGS2	Cyclooxygenase-2 (COX-2)
NM_000379	XDH	xanthine dehydrogenase

Analysis of the expression level of the gene or protein can be performed using a microarray, PCR, NGS (Nest Generation Sequencing), Western blot, northern blot, ELISA, radioimmunoassay, radioimmunoassay, tissue immuno staining, Can be analyzed using a variety of analytical methods known in the art.

Damage to the skin cells is caused by fine dust, which leads to inflammation and further damage to the skin cells. Thus, the skin condition can be improved by taking care of the vicious cycle of the skin cell damage by the peppermint extract.

Another aspect of the present invention includes anti-aging and anti-inflammatory uses of the composition of the present invention.

In another aspect of the present invention there is provided a method for anti-aging a subject comprising administering an effective amount of a Mentha Arvensis extract to a subject in need thereof.

Another aspect of the present invention provides the use of Mentha Arvensis extract in preparing a composition for antiaging .

Peppermint for anti-aging in a further aspect of the invention second (Mentha Arvensis < / RTI > extract.

In another aspect of the present invention there is provided a method for anti-inflammation of a subject comprising administering an effective amount of a Mentha Arvensis extract to a subject in need thereof.

Another aspect of the present invention provides the use of Mentha Arvensis extract in preparing a composition for anti-inflammation.

Peppermint seconds for the anti-inflammatory properties in a further aspect of the present invention (Mentha Arvensis < / RTI > extract.

In one aspect, the present invention provides a composition for inhibiting inflammation or aging by modulating the expression level of a specific gene in a skin cell damaged by inflammation or aging stimulation to a normal level.

Specifically, IL-1a (NM_000575), IL-1B (NM_000576), PTGS2 (NM_000963), XDH (NM_000379) and the like are examples of genes in the skin cells to which the expression level is affected by inflammation or aging stimulation in the present invention . Since the expression levels of IL-1a (NM_000575), IL-1B (NM_000576), PTGS2 (NM_000963) and XDH (NM_000379) are increased by inflammation or aging stimulation, Thereby inhibiting inflammation or aging of the skin cells.

In one aspect, genes whose expression levels are increased by inflammation or aging stimulation used in the present invention are shown in Table 2. In the table, Name means the genebank accession ID of NCBI, Gene Symbol means the official gene symbol, and Gene title means the name of each gene.

Increase gene
Name	GeneSymbol	Gene title
NM_000576	IL1B	interleukin 1, beta
NM_000575	IL1A	interleukin 1, alpha
NM_000963	PTGS2	Cyclooxygenase-2 (COX-2)
NM_000379	XDH	xanthine dehydrogenase

Another aspect of the invention includes the use of the composition of the present invention to enhance skin barrier.

In one aspect, the present invention provides a composition for enhancing skin barrier by regulating the expression level of a specific gene in skin cells damaged by a stimulus causing skin barrier weakness to a normal level.

Specifically, in the present invention, the genes in the skin cells to which the expression level is influenced by the stimuli that cause skin barrier weakness include S100A7 (NM_002963), IL-36G (NM_019618), and LCE3D (NM_032563). Since the expression levels of S100A7 (NM_002963), IL-36G (NM_019618) and LCE3D (NM_032563) are increased by stimulation that causes skin barrier weakness, the expression level of these genes is suppressed and regulated to a normal level .

In one aspect, the genes whose expression levels are increased by the stimuli causing skin barrier weakness used in the present invention are shown in [Table 3]. In the table, Name means the genebank accession ID of NCBI, Gene Symbol means the official gene symbol, and Gene title means the name of each gene.

Increase gene
Name	GeneSymbol	Gene title
NM_002963	S100A7	S100 calcium binding protein A7
NM_019618	IL36G	interleukin 36, gamma
NM_032563	LCE3D	late cornified envelope 3D

A method for reinforcing skin barrier of the subject In another aspect of the invention, the method peppermint second (Mentha Comprising administering an effective amount of an Arvensis extract to a subject in need thereof.

Peppermint seconds in the manufacture of a composition for strengthening the skin barrier in a further aspect of the present invention (Mentha Arvensis ) extracts.

Mint seconds to strengthen the skin barrier in another aspect of the present invention (Mentha Arvensis < / RTI > extract.

In one aspect of the present invention, the composition may be a cosmetic composition, a pharmaceutical composition, or a health functional food composition.

Examples of the cosmetic composition include cosmetics such as various creams, lotion creams, lotions, skins, and the like, and cleansing, cleansing agents, soaps, and essences.

In one aspect, the cosmetic composition to which the composition containing the mint extract of the present invention is added may take the form of a solution, an emulsion, a viscous mixture or the like.

That is, in one aspect, the cosmetic of the present invention is not particularly limited in its formulation, and examples thereof include an emulsion, cream, lotion, essence, pack, gel, powder, makeup base, foundation, lotion, ointment, patch, Formulations such as foam, cleansing cream, cleansing water, body lotion, body cream, body oil, body essence, shampoo, rinse, body cleanser, soap, hair dye, spray and the like.

In the cosmetic composition of each formulation, the ingredients other than the mint extract may be mixed and selected without difficulty by those skilled in the art depending on the formulations of the other cosmetics or the purpose of use.

In addition, in one aspect, the cosmetic of the present invention may comprise a composition selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, high molecular weight peptides, polymeric polysaccharides, sphingolipids and seaweed extracts.

In one aspect, the cosmetic composition of the present invention may contain, in addition to the above essential ingredients, other ingredients usually added to cosmetics, if necessary.

Examples of the compounding ingredients that may be added include organic solvents such as a preservative component, a moisturizer, an emollient, a surfactant, an organic and inorganic pigment, an organic powder, an ultraviolet absorbent, a preservative, a bactericide, an antioxidant, a plant extract, a pH adjuster, A blood circulation accelerator, a cold agent, an antiperspirant agent, and purified water.

The components to be added in addition to these components are not limited thereto, and any of the above components can be compounded within a range that does not impair the objects and effects of the present invention.

In one aspect, the pharmaceutical compositions comprising the peppermint extract of the present invention may further comprise suitable carriers, excipients and diluents conventionally used in the manufacture of pharmaceutical compositions.

The pharmaceutical composition containing the mint extract may be formulated into tablets, capsules, powders or syrups, or external preparations such as ointments, gels, creams, patches or sprays according to a conventional method, And can be formulated and used in any form suitable for pharmaceutical preparations.

In general, it is to be understood that the actual dosage of the active ingredient administered by the pharmaceutical composition should be determined in light of various relevant factors such as the severity of the symptoms, the route of administration selected, the age, sex, weight and health status of the subject. In general, the dosage of the active ingredient may be from 0.0001 mg / kg / day to 3000 mg / kg / day, for example from 10 mg / kg / day to 500 mg / kg / day.

In the health functional food composition as one aspect of the present invention, the health food is produced by using a raw material or a component (functional raw material) having a function useful for a nutrient or a human body which is likely to be deficient in a daily meal, Or to maintain or improve health through the activation of physiological functions. However, the present invention is not limited thereto. The health food may be manufactured and processed in the form of tablets, capsules, powders, granules, liquids, and circles, but is not limited thereto and may be manufactured and processed in any form according to the law.

Specifically, the health beverage composition has no particular limitation on the other ingredients other than the above-mentioned compounds as essential ingredients in the indicated ratios, and may contain various flavors or natural carbohydrates as additional ingredients such as ordinary beverages. Examples of natural carbohydrates are conventional sugars such as monosaccharide polysaccharides, cyclodextrins and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavors (tau martin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.) can be used as flavorings other than those described above.

In general, it should be understood that the actual dosage of the active ingredient administered by the health functional food composition should be determined in light of various relevant factors such as the severity of the symptoms, the selected route of administration, the age, sex, weight and health status of the subject . In general, the dosage of the active ingredient may be from 0.0001 mg / kg / day to 1000 mg / kg / day, for example from 0.02 mg / kg / day to 6 mg / kg / day.

Hereinafter, the configuration and effects of the present invention will be described in more detail with reference to examples. However, these examples are provided for illustrative purposes only in order to facilitate understanding of the present invention, and the scope and scope of the present invention are not limited by the following examples.

[Example 1] Production of mint extract

Mint leaf and Acetobacter aceti were prepared, and they were fermented at 26 DEG C for 48 hours. Then, the fermented product was extracted with an extraction solvent obtained by mixing purified water and ethanol at a ratio of 3: 7, that is, 70% ethanol as an extraction solvent at room temperature. After extracting at room temperature, primary filtration was performed to remove the solid material contained in the extract. Then, the extract was concentrated to remove ethanol, and then it was separated and purified. After centrifugation, secondary filtration and drying, the extracts were obtained.

[Example 2] Fine dust collection and extraction

The filter pack was used for about 24 hours by replacing the filter and denuder at around 10:00 am on each measurement day. The filter pack and the denuder were replaced by a low volume air sampler (Sensidyne, Gillian, Low Volume Air Sampler, FL, USA) Respectively. For 28 days, fine dust was collected daily from the windy area of Seoul (Gyeonggi-do, Korea), and the measurement time was measured by turning on the timer while turning on the vacuum pump and turning off the timer Time was recorded. The flow rate was measured with a flow meter (Model 4143, TSI Inc.) at the start of the measurement at a flow rate of 16.7 L / min, and the flow rate was measured again at the end of the measurement. The Teflon filter in the filter pack weighed before and after sampling. Before measuring the weight of the Teflon filter, the sample was weighed into a desiccator (NIKKO, Japan) with a relative humidity of 40% for 24 hours and then weighed twice on an electronic balance (DVG215CD, Ohaus) . After the sample was collected, the sample was weighed in a desiccator for 24 hours before measuring the weight, and then the weight was measured twice, and the mass concentration was calculated by comparing with the weight measured before the sampling. The extraction of fine dust was carried out by wetting the Teflon filter with 1 mL of ethanol, placing the filter with 14 mL of DW, closing the lid with the filter surface of the filter touching the water surface, and ultrasonically applying the filter with the ultrasonic cleaner for 30 minutes. In order to minimize the error caused by moisture in the filtration step, the water content of the filter was completely removed for 48 hours in a decicator, and then the weight of the filter was measured using a super-precision scale system (Mettler Toledo Company) Weighed and weighed before and after filter extraction.

[Example 3] Culture of keratinocyte (normal human) cell line

Human normal epidermal keratinocytes were purchased from Lonza, Inc. (Walkersville, Maryland, USA), subcultured and cultured in a CO 2 incubator at 37 ° C under 5% CO 2 Lt; / RTI > The cell culture was in accordance with Lonza's guidelines. (KGM-2 Bullet kit, CC-4152) (ingredient: BPE (bovine pituitary extract)), human epidermal growths (KBM- (Gentamycin Suflate + Amphofericin-B: GA), human epidermal growth factor (hEGF), insulin, Hydrocortisone, Transferrin, Epinephrine and gentamycin sulfate (KGM-2 Bullet Kit, CC-3107) was added to the reaction mixture.

[Example 4] (normal human) Treatment of fine dust and cytotoxicity measurement on keratinocyte cell line

MTT experiments were carried out using keratinocyte lines (normal human) by the method of Mossman et al. (J. Immunol. Methods, 65, 55-63, 1983) in order to confirm cytotoxicity through fine dusting.

Specifically, a fine dust having a diameter of 2.5 占 퐉 obtained by using the 24-well plate and obtained in Example 2 was dispersed in purified water to prepare a fine dust dispersion. Then, 2.5 占 퐉 10 ⁵ Cells cultured under the conditions of the number of well cells were treated with the fine dust dispersion and cultured for 24 hours. Then, 5 mg / ml of MTT (3-4,5-dimethylthiazol-2,5-diphenyltetra zolium bromide) Lt; 0 > C for 3 hours. The medium was then removed and the formazan crystal formed was dissolved in 500 占 퐇 of DMSO. The lysate was transferred to a 96-well plate and aliquoted and the OD value measured at 540 nm absorbance. The measurement results are shown in Fig.

As shown in FIG. 1, the concentration (IC20) showing an 80% survival rate with respect to cytotoxicity by a dispersion in which fine particles of 2.5 micrometer or less were dispersed in the cell line was 12.5 g / Ml.

[Example 5] Confirmation of cellular genetic change of fine dust through next generation sequencing

For RNA-base sequence data processing and analysis, reference was made to the general analysis step developed by Trapnell et al. (2012). We confirmed the RNA-seq data quality using FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) and used FASTX (http://hannonlab.cshl.edu/fastx_toolkit/) , Thereby removing the base and the adder sequences with low accuracy. Afterwards, alignment was performed using Tophat (Trapnell et al., 2009) and human genome (hg19), and the amount of data for each sample was confirmed using EVER-seq renamed RSeQC (Wang et al., 2012 ). In addition, the level of expression of transcripts was quantified using Cufflinks, and transcription levels were compared between the fine dust dispersion treated and normal samples (Trapnell et al., 2010). A stringent cutoff of ≥2.0 fold-change was applied to the FDR adjusted p-value <0.05 to determine the gene that showed significant expression differences in the treatment of the dispersion of fine dust with a diameter of 2.5 μm. The measurement results are shown in the following [Table 4] and [Figure 2a] to [Figure 2g].

Increase gene
Name	GeneSymbol	Drainage variation
NM_000575	IL-1a	4.014605674
NM_000576	IL1B	11.31259177
NM_019618	IL36G	6.742761413
NM_002963	S100A7	9.515833375
NM_032563	LCE3D	11.96124722
NM_000963	PTGS2	2.284968542
NM_000379	XDH	2.57463302

[Example 6] Real-time RT-PCR quantitation

Human microkeratin skin cells cultured in Example 3 in the amount of fine particles having a diameter of 2.5 占 퐉 extracted in Example 2 were treated in an amount of 12.5 占 퐇 in 1 ml of the cell culture medium and applied to the applied biosystems TaqMan® Primers) to determine the relative mRNA expression levels. The extract prepared in Example 1 was used.

Increase gene
Name	GeneSymbol	TaqMan® primer
NM_000575	IL-1a	Hs00174092_m1
NM_000576	IL1B	Hs01555410_m1
NM_019618	IL36G	Hs00219742_m1
NM_002963	S100A7	Hs00161488_m1
NM_032563	LCE3D	Hs00754375_s1
NM_000963	PTGS2	Hs00153133_m1
NM_000379	XDH	Hs00166010_m1

After 24 hours, the culture medium was removed. Cells were washed with 2 ml of phosphate buffered saline (PBS), and then treated with Trizol reagent (Invitrogen, Carlsbad, CA, USA). The separated RNA was further purified with an RNA kit (QIAGEN RNeasykt, QIAGEN, Valencia, Calif.) From Agilent Technologies, Inc., Agilent 2100 BioAnalyzer, Agilent Technologies, Santa Clara, ) Was used to confirm the quality of the RNA. CDNA was synthesized from the above RNA using a reverse transcription kit (Invitrogen, Carlsbad, Calif.) Of Invitrogen. RT-PCR was performed using the primers shown in Table 5 -RT-PCR: real-time reverse transcription polymerase chain reaction). The gene expression patterns of the cells were evaluated by real-time PCR using a TaqMan gene expression assay kit (Applied Biosystems, Foster City, Calif.) Of Applied Biosystems. Respectively. Both Q-RT-PCR and real-time PCR were performed according to the standard protocols distributed by Life Technologies. Specifically, the Q-RT-PCR was performed at 95 ° C for 20 seconds, followed by 95 ° C for 3 seconds and 60 ° C for 30 seconds For 40 cycles.

As shown in FIGS. 3A to 3G, there is a gene whose expression level is increased or decreased in skin cells stimulated by fine dust, and the expression of interleukin-1 alpha (IL-1a) Interleukin 1 Beta (IL-1B), Interleukin 36 Gamma (IL-36G), S100 Calcium Binding Protein A7 (S100A7), Latex Keratinocyte 3D (LCE3D), Prostaglandin-Endo Peroxide Synthase 2 (PTGS2) And the amount of dehydrogenase (XDH) gene expression was decreased.

In addition, as shown in FIGS. 3A to 3G, there is a gene whose expression level is increased in skin cells stimulated by inflammation or aging stimulation, and the expression of interleukin 1 alpha (IL-1a ), Interleukin 1 beta (IL-1B), prostaglandin-endo peroxidase 2 (PTGS2) and xanthine dehydrogenase (XDH) gene.

Therefore, the extract of mint is effective for protecting skin cells from skin cell damage due to irritation or aging stimulation, and inhibiting or preventing the change in the expression amount of the specific gene described above by inflammation or aging stimulation, As shown in FIG.

In addition, as shown in FIGS. 3A to 3G, there is a gene whose expression level is increased in skin cells stimulated by a stimulus causing weakening of the skin barrier, and the expression of interleukin 36 gamma (IL) -36G), S100 calcium-binding protein A7 (S100A7), and late keratin hyaluronan 3D (LCE3D) gene.

Accordingly, the mint extract has an effect of effectively protecting skin cells from skin cell damage caused by stimulation that causes skin barrier weakness, inhibiting or preventing the change in the expression amount of the specific gene described above by stimulation that causes skin barrier weakness, Lt; RTI ID = 0.0 &gt; of &lt; / RTI &gt;

Thus, it has been found that the extract of peppermint larvae effectively protects skin cells from stimulation by fine dusts, and inhibits or prevents the change in the expression level of the above-mentioned specific gene by the stimulation, .

Hereinafter, formulation examples of the composition according to the present invention will be described. However, the cosmetic composition, the pharmaceutical composition and the health functional food composition can be applied to various formulations, and the present invention is not limited thereto .

 [Formulation Example 1] Tablets

The tablets were prepared by mixing 100 mg of mint extract, 400 mg of lactose, 400 mg of corn starch and 2 mg of magnesium stearate according to the examples of the present invention, followed by tableting according to a conventional preparation method of tablets.

Compounding ingredient	Content (mg)
Mint extract	100
Lactose	400
Corn starch	400
Magnesium stearate	2

[Formulation Example 2]

100 mg of mint extract, 400 mg of lactose, 400 mg of corn starch and 2 mg of magnesium stearate according to the present invention were mixed and filled in gelatin capsules according to the conventional preparation method of capsules to prepare capsules.

Compounding ingredient	Content (mg)
Mint extract	100
Lactose	400
Corn starch	400
Magnesium stearate	2

[Formulation Example 3]

50 mg of mint extract, 250 mg of anhydrous crystalline glucose and 550 mg of starch according to the present invention were mixed and granulated into granules using a fluidized bed granulator and filled in a capsule.

Compounding ingredient	Content (mg)
Mint extract	50
Anhydrous crystalline glucose	250
Starch	550

[Formulation Example 4] Soap

Compounding ingredient	content(%)
Mint extract	5.00
maintain	Suitable amount
Sodium hydroxide	Suitable amount
Sodium chloride	Suitable amount
Spices	Suitable amount
Purified water	Balance

[Formulation Example 5] Lotion

Compounding ingredient	content(%)
Mint extract	5.00
L-ascorbic acid-2-phosphate magnesium salt	1.00
Water soluble collagen (1% aqueous solution)	1.00
Sodium citrate	0.10
Citric acid	0.05
Licorice extract	0.20
1,3-butylene glycol	3.00
Purified water	Balance

[Formulation Example 6] Cream

Compounding ingredient	content(%)
Mint extract	3.00
Polyethylene glycol monostearate	2.00
Self emulsifying monostearic acid glycerin	5.00
Cetyl alcohol	4.00
Squalene	6.00
Tri-2-ethylhexanoic acid glyceryl	6.00
Sphingoglycolipids	1.00
1,3-butylene glycol	7.00
Purified water	Balance

[Formulation Example 7] ointment

Compounding ingredient	content(%)
Mint extract	5.00
Polyvinyl alcohol	13.00
L-ascorbic acid-2-phosphate magnesium salt	1.00
Lauroylhydroxyproline	1.00
Water soluble collagen (1% aqueous solution)	2.00
1,3-butylene glycol	3.00
ethanol	5.00
Purified water	Balance

 [Formulation Example 8] Preparation of serum

Compounding ingredient	content(%)
Mint extract	3.00
Hydroxyethylene cellulose (2% aqueous solution)	12.00
Xanthan gum (2% aqueous solution)	2.00
1,3-butylene glycol	6.00
Concentrated glycerin	4.00
Sodium hyaluronate (1% aqueous solution)	2.00
Purified water	Balance

[Formulation Example 9] Health food

Compounding ingredient	content
Mint extract	2 mg
Vitamin A acetate	70 μg
Vitamin E	1.0 mg
Vitamin B1	0.13 mg
Vitamin B2	0.15 mg
Vitamin B6	0.5 mg
Vitamin B12	0.2 μg
Vitamin C	10 mg
Biotin	10 μg
Nicotinic acid amide	1.7 mg
Folic acid	50 μg
Calcium pantothenate	0.5 mg
Ferrous sulfate	1.75 mg
Zinc oxide	0.82 mg
Magnesium carbonate	25.3 mg
Potassium monophosphate	15 mg
Dicalcium phosphate	55 mg
Potassium citrate	90 mg
Calcium carbonate	100 mg
Magnesium chloride	24.8 mg

[Formulation Example 10] Health drinks

Compounding ingredient	content
Mint extract	50 mg
Citric acid	1000 mg
oligosaccharide	100 g
Taurine	1g
Purified water	Balance

Claims (19)

1. Mentha Arvensis ) extract as an active ingredient.
2. The method according to claim 1,

   Wherein the skin damage care by the fine dust is at least one selected from the group consisting of skin barrier strengthening, anti-aging, and anti-inflammation.
3. MintMentha Arvensis) Extract as an active ingredient.
4. Mentha Arvensis ) extract as an active ingredient.
5. Mentha Arvensis ) extract as an active ingredient.
6. 6. The method according to any one of claims 1 to 5,

   Wherein the mint extract is included in an amount of 0.000001 to 30% by weight based on the total weight of the composition.
7. 6. The method according to any one of claims 1 to 5,

   Wherein the extract comprises at least one selected from the group consisting of water, C ₁ - C ₆ anhydrous or lower alcohol, acetone, butylene glycol, ethyl acetate, diethyl acetate, diethyl ether, benzene, chloroform and hexane &Lt; / RTI &gt; is extracted with a solvent.
8. 6. The method according to any one of claims 1 to 5,

   Wherein the mint extract is extracted from a leaf of mint leaf.
9. 6. The method according to any one of claims 1 to 5,

   Wherein said mint is fermented mint juice,

   The fermentation can be carried out in the presence of an Acetobacter sp . ) Microbes are added and fermented.
10. 10. The method of claim 9,

    The acetonitrile in bakteo (Acetovacter sp . ) The microorganism is Acetobacter aceti .
11. 3. The method according to any one of claims 1 to 2,

    Wherein said composition is selected from the group consisting of IL-1a (NM_000575), IL-1B (NM_000576), IL-36G (NM_019618), S100A7 (NM_002963), LCE3D (NM_032563), PTGS2 (NM_000963), XDH Lt; / RTI &gt;
12. The method of claim 3,

    Wherein said composition inhibits expression of at least one selected from the group consisting of IL-36G (NM_019618), S100A7 (NM_002963) and LCE3D (NM_032563).
13. 5. The method of claim 4,

    Wherein the composition inhibits expression of at least one selected from the group consisting of IL-1a (NM_000575), IL-1B (NM_000576), PTGS2 (NM_000963) and XDH (NM_000379).
14. 6. The method of claim 5,

    Wherein said composition inhibits expression of at least one selected from the group consisting of IL-1a (NM_000575), IL-1B (NM_000576) and PTGS2 (NM_000963).
15. 15. The method according to any one of claims 11 to 14,

    Wherein the composition is applied to keratinocytes.
16. 6. The method according to any one of claims 1 to 5,

    Wherein the mint extract is administered at a dose of 10 to 500 mg / kg / day.
17. 6. The method according to any one of claims 1 to 5,

    Wherein the composition is a cosmetic composition.
18. 6. The method according to any one of claims 1 to 5,

    Wherein the composition is a pharmaceutical composition.
19. 6. The method according to any one of claims 1 to 5,

    Wherein the composition is a health functional food composition.

Images